Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Thursday 11 June, 2009

Summit Corporation PLC

Holding(s) in Company

Summit Corporation plc
("Summit" or "the Company")


Oxford, UK, 11 June 2009 - Summit Corporation plc (AIM: SUMM), the UK
drug discovery company, has received notification that Barclays PLC
no longer has a disclosable interest in Summit's issued ordinary

For further information please contact:

Summit Corporation PLC
Steven Lee, PhD
Richard Pye, PhD
Tel: +44 (0)1235 443951

Panmure Gordon (Nominated adviser and Broker)
Andrew Burnett / Rakesh Sharma (Corporate Finance)
Ashton Clanfield (Corporate Broking)
Tel: +44 (0)207 459 3600

                               - END -
About Summit plc

Summit plc is a UK based drug discovery company with a major focus on
developing new therapeutics from its iminosugar drug discovery
Summit believes iminosugars are the key to gaining access to several
disease mechanisms where classical drugs have had little success, and
thus offer a major opportunity for the discovery and development of
new medicines.
Carbohydrates (sugars) play critical roles in maintaining correct
functioning of many normal processes in healthy individuals and
errors in carbohydrate recognition or modification can lead to
malfunction in cells resulting in disease.  Iminosugars have the
potential to mimic carbohydrates or to interact with processes which
manipulate carbohydrates to modify activity or to correct aberrant
function.  Additionally, iminosugars, due to their sugar-like
properties, have important effects when interacting with many other
unexploited therapeutic targets.
Summit is at the forefront of developing new iminosugar drug
candidates with a focus in two therapeutics areas: anti-infectives
and metabolic diseases.
Commercially, Summit has a track record of signing programme
agreements and currently has an out-licensed product portfolio
comprising of seven drug programmes with BioMarin, Orient Europharma,
Evolva and the Lilly TB Drug Discovery Initiative.  In the future
these programmes may generate success based milestone payments and
royalties for Summit.
In addition, Summit owns Dextra Laboratories, a business unit that
operates independently to Summit, which offers specialist
carbohydrate chemistry services to third parties on a fee-for-service
or collaborative basis.
The company listed on the alternative investment market (AIM) of the
London Stock Exchange in October 2004 - symbol: SUMM.  Further
information about the company is available at


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.